Lilly Zyprexa (correction)
Executive Summary
Lilly received an "approvable" letter from FDA on April 30 for its submission of two sNDAs for Zyprexa (olanzapine) for the treatment of schizophrenia and acute mixed or manic episodes associated with bipolar I disorder in adolescents, ages 13 to 17. A recent article in "The Pink Sheet" misstates the ages for proposed pediatric indications (1"The Pink Sheet" June 25, 2007, In Brief)...